Moeller BJ, Richardson RA, Dewhirst MW: Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007, 26: 241–248. 10.1007/s10555-007-9056-0
Article
CAS
PubMed
Google Scholar
Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med 2007, 85: 1301–1307. 10.1007/s00109-007-0281-3
Article
PubMed
Google Scholar
Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26: 281–290. 10.1007/s10555-007-9066-y
Article
CAS
PubMed
Google Scholar
Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 2008, 8: 967–975. 10.1038/nrc2540
Article
CAS
PubMed
Google Scholar
Bristow RG, Hill RP: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8: 180–192. 10.1038/nrc2344
Article
CAS
PubMed
Google Scholar
Dewhirst MW, Cao Y, Moeller B: Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008, 8: 425–437. 10.1038/nrc2397
Article
CAS
PubMed
Google Scholar
Lunt SJ, Chaudary N, Hill RP: The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009, 26: 19–34. 10.1007/s10585-008-9182-2
Article
PubMed
Google Scholar
Pires IM, Bencokova Z, Milani M, Folkes LK, Li J-L, Stratford MR, Harris AL, Hammond EM: Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 2010, 70: 925–935. 10.1158/0008-5472.CAN-09-2715
Article
CAS
PubMed
Google Scholar
Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terriis DJ, Overgaard J: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77: 18–24. 10.1016/j.radonc.2005.06.038
Article
PubMed
Google Scholar
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56: 4509–4515.
CAS
PubMed
Google Scholar
Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L, Hill RP: Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 2006, 80: 132–137. 10.1016/j.radonc.2006.07.014
Article
PubMed
Google Scholar
Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA: Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36: 417–428. 10.1016/S0360-3016(96)00325-2
Article
CAS
PubMed
Google Scholar
Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA: [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003, 30: 695–704. 10.1007/s00259-002-1096-7
Article
CAS
PubMed
Google Scholar
Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI: Initial results of hypoxia imaging using 1-alpha- D : -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009, 36: 1565–1573. 10.1007/s00259-009-1154-5
Article
CAS
PubMed
Google Scholar
Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, Desmond T, Meyer C, Piert M: Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011, 38: 1816–1823. 10.1007/s00259-011-1876-z
Article
PubMed
Google Scholar
Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV: [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. App Radiat Isot 2001, 54: 73–80. 10.1016/S0969-8043(00)00102-0
Article
CAS
Google Scholar
Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S, Sipila H, Evans SM, Solin O, Minn H: 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008, 49: 1944–1951. 10.2967/jnumed.108.053785
Article
PubMed
Google Scholar
Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, Grenman R, Minn H: Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 59: 971–982. 10.1016/j.ijrobp.2003.12.014
Article
PubMed
Google Scholar
Yue J, Yang Y, Cabrera AR, Sun X, Zhao S, Xie P, Zheng J, Ma L, Fu Z, Yu J: Measuring tumor hypoxia with (1)(8)F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Dis Esophagus 2012, 25: 54–61. 10.1111/j.1442-2050.2011.01209.x
Article
CAS
PubMed
Google Scholar
Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA: An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008, 49: 1177–1182. 10.2967/jnumed.108.051326
Article
PubMed
Google Scholar
Copper Cu 64-ATSM and PET/CT scan in predicting disease progression in patients with newly-diagnosed stage IB, stage II, stage III, or stage IVA cervical cancer who are undergoing chemoradiotherapy per NCCN guidelines (ACRIN 6682). http://clinicaltrials.gov/ct2/show/NCT00794339
Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ: Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49: 201–205. 10.2967/jnumed.107.048520
Article
CAS
PubMed
Google Scholar
Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, Omura M, Odagiri K, Tohnai I, Inoue T, Tateishi U: Assessment of tumor hypoxia by Cu-62-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011, 25: 339–345. 10.1007/s12149-011-0471-5
Article
PubMed
Google Scholar
Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M: Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005, 5: 152. 10.1186/1471-2407-5-152
Article
PubMed
Google Scholar
Wang WL, Lee NY, Georgi JC, Narayanan M, Guillem J, Schoder H, Humm JL: Pharmacokinetic analysis of hypoxia F-18-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med 2010, 51: 37–45. 10.2967/jnumed.109.067009
Article
PubMed
Google Scholar
Schneider RF, Engelhardt EL, Stobbe CC, Fenning MC, Chapman JD: The synthesis and radiolabelling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. J Labelled Comp Radiopharm 1997, 39: 541–557. 10.1002/(SICI)1099-1344(199707)39:7<541::AID-JLCR5>3.0.CO;2-B
Article
CAS
Google Scholar
Zanzonico P, O’Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C: Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004, 31: 117–128. 10.1007/s00259-003-1322-y
Article
PubMed
Google Scholar
Riedl CC, Brader P, Zanzonico PB, Chun YS, Woo Y, Singh P, Carlin S, Wen B, Ling CC, Hricak H, Fong Y: Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology 2008, 248: 561–570. 10.1148/radiol.2482071421
Article
PubMed
Google Scholar
Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46: 1023–1027.
PubMed
Google Scholar
ICRP: Limits for intakes of radionuclides by workers. ICRP publication 30 (part 1). Ann ICRP 1979, 2: 3–4.
Google Scholar
ICRP: Basic anatomical and physiological data for use in radiological protection reference values. ICRP publication 89. Ann ICRP 2002, 32: 3–4. 10.1016/S0146-6453(02)00020-9
Article
Google Scholar
ICRP: 1990 Recommendations of the International Commission on Radiological Protection. ICRP publication 60. Ann ICRP 1991, 21: 1–3.
Article
Google Scholar
Suehiro M, Burgman P, Carlin S, Burke S, Yang GB, Ouerfelli O, Oehler-Janne C, O’Donoghue J, Ling C, Humm J: Radiosynthesis of I-131 IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker? Nucl Med Biol 2009, 36: 477–487. 10.1016/j.nucmedbio.2009.03.002
Article
CAS
PubMed
Google Scholar
Li XF, Sun XR, Ma YY, Suehiro M, Zhang MT, Russell J, Humm JL, Ling CC, O’Donoghue JA: Detection of hypoxia in microscopic tumors using I-131-labeled iodo-azomycin galactopyranoside (I-131-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 2010, 37: 339–348. 10.1007/s00259-009-1310-y
Article
PubMed
Google Scholar
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007, 8: 304–310. 10.1016/S1470-2045(07)70044-X
Article
CAS
PubMed
Google Scholar
Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM: (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med 2011, 52: 1173–1180. 10.2967/jnumed.110.086165
Article
PubMed
Google Scholar